Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes
Kristine Broglio(Berry & Associates (United States)), Donald A. Berry(Berry & Associates (United States)), Christine Brezden‐Masley(Mount Sinai Hospital), Alexander Paterson, Margaret Foster(NHS Wales Shared Services Partnership), Karen A. Gelmon(University of British Columbia), Melanie Quintana(Berry & Associates (United States)), Daniel Rayson, Stephen Chia(BC Cancer Agency), Anna McGlothlin(Berry & Associates (United States)), Susan Dent(Washington Hospital), Scott Berry(Queen's University), Jean-François Boileau(McGill University), Melissa Olinger(Berry & Associates (United States))
Cited by 375
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k